Crescent Biopharma (CBIO) Competitors $13.79 -0.14 (-1.01%) As of 08/15/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesOwnershipSEC FilingsSustainabilityTrendsBuy This Stock CBIO vs. GERN, ZBIO, RIGL, LXRX, MYGN, XOMA, VSTM, EBS, VNDA, and CDXSShould you be buying Crescent Biopharma stock or one of its competitors? The main competitors of Crescent Biopharma include Geron (GERN), Zenas BioPharma (ZBIO), Rigel Pharmaceuticals (RIGL), Lexicon Pharmaceuticals (LXRX), Myriad Genetics (MYGN), XOMA Royalty (XOMA), Verastem (VSTM), Emergent Biosolutions (EBS), Vanda Pharmaceuticals (VNDA), and Codexis (CDXS). These companies are all part of the "biotechnology" industry. Crescent Biopharma vs. Its Competitors Geron Zenas BioPharma Rigel Pharmaceuticals Lexicon Pharmaceuticals Myriad Genetics XOMA Royalty Verastem Emergent Biosolutions Vanda Pharmaceuticals Codexis Geron (NASDAQ:GERN) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership. Which has more risk and volatility, GERN or CBIO? Geron has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Crescent Biopharma has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500. Do institutionals and insiders have more ownership in GERN or CBIO? 73.7% of Geron shares are held by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are held by institutional investors. 7.4% of Geron shares are held by insiders. Comparatively, 4.0% of Crescent Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is GERN or CBIO more profitable? Crescent Biopharma has a net margin of 0.00% compared to Geron's net margin of -53.52%. Geron's return on equity of -31.37% beat Crescent Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Geron-53.52% -31.37% -16.01% Crescent Biopharma N/A -106.06%-86.60% Do analysts recommend GERN or CBIO? Geron presently has a consensus target price of $4.19, indicating a potential upside of 188.79%. Crescent Biopharma has a consensus target price of $25.50, indicating a potential upside of 84.92%. Given Geron's higher possible upside, analysts plainly believe Geron is more favorable than Crescent Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Geron 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.56Crescent Biopharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40 Which has stronger earnings and valuation, GERN or CBIO? Crescent Biopharma has lower revenue, but higher earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeron$76.99M12.02-$174.57M-$0.13-11.15Crescent Biopharma$10K26,959.45-$37.88M-$34.93-0.39 Does the media favor GERN or CBIO? In the previous week, Geron had 14 more articles in the media than Crescent Biopharma. MarketBeat recorded 26 mentions for Geron and 12 mentions for Crescent Biopharma. Geron's average media sentiment score of 0.78 beat Crescent Biopharma's score of 0.58 indicating that Geron is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Geron 6 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Crescent Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryGeron beats Crescent Biopharma on 9 of the 17 factors compared between the two stocks. Get Crescent Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CBIO vs. The Competition Export to ExcelMetricCrescent BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$272.33M$2.75B$5.66B$9.82BDividend YieldN/A1.78%3.79%4.07%P/E Ratio-0.3921.8930.5825.12Price / Sales26,959.45735.85462.42114.82Price / CashN/A177.1637.4059.05Price / Book1.995.079.096.18Net Income-$37.88M$31.61M$3.25B$264.89M7 Day Performance7.32%25.12%7.32%4.18%1 Month Performance4.95%3.84%5.41%1.99%1 Year PerformanceN/A10.43%30.66%24.22% Crescent Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CBIOCrescent Biopharma3.8306 of 5 stars$13.79-1.0%$25.50+84.9%N/A$272.33M$10K-0.3950News CoverageAnalyst RevisionGERNGeron3.3542 of 5 stars$1.23+1.2%$4.61+276.4%-67.5%$780.23M$116.29M-5.83229Analyst RevisionZBIOZenas BioPharma1.7201 of 5 stars$15.87-5.6%$36.67+131.0%N/A$663.84M$5M-4.47N/ANews CoverageEarnings ReportUpcoming EarningsAnalyst DowngradeAnalyst RevisionRIGLRigel Pharmaceuticals1.8569 of 5 stars$23.34+3.0%$36.40+56.0%+216.8%$416.69M$179.28M11.26160LXRXLexicon Pharmaceuticals2.8925 of 5 stars$1.06-5.8%$3.67+247.6%-24.4%$381.37M$31.21M-2.07140Positive NewsMYGNMyriad Genetics3.6399 of 5 stars$3.90-2.1%$14.38+269.3%-79.5%$360.87M$831.30M-3.502,700XOMAXOMA Royalty4.4179 of 5 stars$27.60+1.3%$69.50+151.9%+12.8%$330.23M$13.05M-24.0010News CoverageEarnings ReportAnalyst UpgradeAnalyst RevisionVSTMVerastem3.1092 of 5 stars$5.93-1.3%$13.38+125.5%+252.8%$327.77M$10M-1.8650Analyst UpgradeGap DownEBSEmergent Biosolutions4.7132 of 5 stars$6.01+0.9%$14.33+138.7%+2.2%$325.94M$930.30M-2.222,420News CoverageVNDAVanda Pharmaceuticals4.4694 of 5 stars$4.19-1.8%$16.50+294.3%-15.7%$246.64M$203.47M-3.70290News CoverageAnalyst RevisionCDXSCodexis3.6615 of 5 stars$2.84+0.1%$11.00+286.8%+7.1%$237.37M$59.35M-2.89250News CoverageEarnings ReportAnalyst UpgradeAnalyst Revision Related Companies and Tools Related Companies Geron Competitors Zenas BioPharma Competitors Rigel Pharmaceuticals Competitors Lexicon Pharmaceuticals Competitors Myriad Genetics Competitors XOMA Royalty Competitors Verastem Competitors Emergent Biosolutions Competitors Vanda Pharmaceuticals Competitors Codexis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CBIO) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crescent Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crescent Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access